13 January 2012 - US Prasco Laboratories said on Thursday it had sealed an agreement with Shire (NASDAQ:SHPGY) to sell in the US the authorised generic version of Shire's Carbatrol (carbamazepine) extended-release capsules in 100 mg, 200 mg and 300 mg.

Financial terms of the deal were not disclosed.

The Carbatrol (carbamazepine) extended-release capsules are AB-rated, therapeutically equivalent and substitutable for the brand Carbatrol. The product will be distributed in the USA under the Prasco label.

Carbatrol is indicated for the treatment of certain types of seizures (partial, tonic-clonic, mixed) and some types of nerve pain (trigeminal and glossopharyngeal neuralgia). However, it is not a regular pain drug and should not be used for aches or pains.